Secretome Therapeutics Raises $30M for Heart Disease Therapy

Secretome Therapeutics has successfully closed a $30 million Series A funding round, with RA Capital Management serving as the sole investor. This significant capital infusion is earmarked to propel the clinical development of the company's lead therapeutic candidate, STM-01, which targets cardiomyopathy associated with Duchenne muscular dystrophy (DMD) and other rare neuromuscular disease-linked cardiomyopathies.

The Plano, Texas-based biopharmaceutical firm intends to leverage these funds to advance STM-01 through crucial Phase 2 and Phase 3 clinical trials. This cellular therapy, derived from neonatal cardiac progenitor cells (nCPC), is engineered to address the inflammatory and fibrotic processes that damage the heart muscle in DMD patients, a population with a pressing need for effective disease-modifying treatments. The prevalence of DMD, while rare, presents a significant unmet medical need, particularly concerning its cardiac complications which often become the primary cause of mortality.

In conjunction with the financing, the company announced the appointment of David Lubner to its Board of Directors. Lubner brings over two and a half decades of extensive experience in the life sciences industry, including instrumental roles at Ra Pharmaceuticals before its acquisition by UCB, and previous financial leadership positions at Tetraphase Pharmaceuticals, PharMetrics, and ProScript. His deep financial and operational expertise is expected to be invaluable as Secretome enters this accelerated growth phase.

Furthermore, Matthew Hammond, Ph.D., MBA, a Partner at RA Capital Management, will join the board as an observer, providing strategic oversight. This development follows the departure of Dr. Charles Edwards from the board, whose contributions were acknowledged during a pivotal period of the company's expansion. Secretome is also actively developing STM-21, a secretome-based therapy currently in preclinical stages, alongside other nCPC-derived treatments for various cardiac conditions and heart failure.

The investment from RA Capital Management underscores a strong market confidence in Secretome's innovative approach to treating complex cardiac conditions. The broader market for rare disease therapies is experiencing robust growth, driven by advancements in genetic medicine and cell-based therapies, with significant investor interest in companies addressing high unmet needs. The global market for cardiovascular drugs alone is projected to reach hundreds of billions of dollars in the coming years, highlighting the immense therapeutic and commercial potential.

“This investment marks a pivotal moment for Secretome, validating our scientific foundation, our dedicated team, and our strategic path forward,” stated Vinny Jindal, President and CEO of Secretome Therapeutics. “With this crucial funding, we are empowered to expedite the development of STM-01, aiming to establish it as a leading therapy for individuals and families impacted by Duchenne muscular dystrophy. We are particularly enthusiastic about the profound financial, operational, and strategic insights David Lubner will contribute to our Board as we embark on this next significant chapter.”

Matthew Hammond of RA Capital Management added, “Secretome is rapidly establishing itself as a frontrunner in the immunology and inflammation space for cardiac disease, and a pioneer in progenitor cell-based therapeutics. We are confident that STM-01 has the potential to be a best-in-class, disease-modifying cellular therapy for DMD patients, and represents the vanguard of Secretome’s promising pipeline of nCPC-based therapies.”